Syneos Health, Inc. announced the appointment of Greg Licholai, MD, as Chief Medical Officer, effective June 1, 2026. In this role, Dr. Licholai will strengthen the organization?s position as a strategic partner to biopharmaceutical companies navigating an increasingly complex drug development environment. Dr. Licholai brought a distinctive blend of experience shaped by seasoned executive leadership.
A physician, trained neurosurgeon, life science executive and entrepreneur associated with multiple successful innovations, he has guided companies through critical inflection points. From early development through commercialization, he has a unique understanding of how scientific, operational and market decisions intersect to drive outcomes and better medicines for patients. Dr. Licholai has led innovation across notable industry organizations, including serving as Chief Medical and Innovation Officer at ICON and President of Rare Disease at Moderna.
He has also built and advised biotechnology companies and was a partner at McKinsey & Company. In addition, Dr. Licholai is on the faculty at the Yale School of Management, has taught at Harvard Business School and serves on the Boards of several nonprofit and patient organizations. He joins a deep bench of therapeutic experts across Oncology/Hematology; Neuroscience; Cardiometabolic; Immunology and Inflammation; General Medicine; and Rare Disease, Cell & Gene Therapy.
